Pharmaceutical intermediates
Danicopan Intermediates
4 pharmaceutical intermediates for Danicopan. Indication: Adult Paroxysmal Nocturnal Hemoglobinuria (PNH).
About Danicopan
- Originator
- Achillion Pharmaceuticals Inc
- Indication
- Adult Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Approved Date
- 03/29/2024
- NCE Patent
- 03/29/2029
- DS/DP
- 02/25/2035
Available intermediates
4 intermediates currently listed for Danicopan. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| (2S,4R)-1-(tert-butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid | 203866-14-2 | / | / |
| 1-(5-Bromo-1H-indazol-3-yl)ethan-1-one | 886363-74-2 | / | / |
| (2S,4R)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide | 1903745-21-0 | / | / |
| 2-MethylpyriMidine-5-boronic Acid Pinacol Ester | 1052686-67-5 | / | / |
Building toward Danicopan?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →